

IRX Therapeutics

IRX Therapeutics to Present at BIO Investor Forum

New York, October 29, 2008 -- IRX Therapeutics, a privately-held company dedicated to the discovery and development of proprietary therapies for the treatment of cancer and viral diseases, today announced that John W. Hadden II, President and Chief Executive Officer, will be making a presentation on October 30, 2008 at 1:45 pm (PDT) during the 7th Annual BIO Investor Forum at The Palace Hotel in San Francisco. Mr. Hadden will provide an overview of the Company's product portfolio and business developments.

About IRX Therapeutics

IRX Therapeutics is a privately-held immunotherapy company founded by John W. Hadden, M.D., a pioneer in the field of Immunopharmacology. The Company's product platform seeks to restore an effective cellular immune response for the treatment of advanced cancers and viral diseases by correcting both dendritic cell and T cell defects.

The Company's lead product, IRX-2, received Fast Track designation by the Food and Drug Administration. Phase 1 and Phase 2 clinical trials in late-stage head and neck cancer patients have been completed.

For more information on IRX Therapeutics, please visit the Company's website at <http://www.irxtherapeutics.com>.

Contacts:

Jeffrey Hwang

jhwang@irxtherapeutics.com

212-582-1199

R. Breck Denny

rbdenny@irxtherapeutics.com

212-582-1199

###